Eliminating senescent cells in fat can alleviate signs of diabetes

Latest articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

It’s time to reboot longevity and healthy aging

Dr Michael Roizen calls for fundamental societal changes to ensure the benefits of longevity and healthy aging are realised. Later this year, best-selling author Michael...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Click the globe for translations.

Deleting dysfunctional cells could lead to game-changing treatments for diabetes and other metabolic diseases.

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from the UConn Center on Aging and UConn School of Medicine have discovered; this could lead to new treatments for Type 2 diabetes and other metabolic diseases.

Longevity.Technology: The cells in your body are constantly renewing themselves, with older cells aging and dying as new ones are being born – but sometimes that process goes awry. Occasionally damaged cells linger; called senescent cells, they hang around, acting as a bad influence on other cells nearby. Their bad influence changes how the neighbouring cells handle sugars or proteins and so causes metabolic problems.

Type 2 diabetes is the most common metabolic disease in the US. About 34 million people, or one out of every 10 inhabitants of the US, suffer from it, according to the federal Centers for Disease Control and Prevention (CDC). Most people with diabetes have insulin resistance, which is associated with obesity, lack of exercise and poor diet. However, it also has a lot to do with senescent cells in people’s body fat, according to new findings by UConn School of Medicine’s Ming Xu and colleagues. And clearing away those senescent cells seems to stop diabetic behavior in obese mice, they report in the Cell Metabolism [1]. Ming Xu, assistant professor in the UConn Center on Aging and the department of Genetics and Genome Sciences at the School of Medicine, led the research, along with UConn researchers Lichao Wang and Binsheng Wang as major contributors.

Alleviating the negative effects of fat on metabolism was a dramatic result, the researchers said. If a therapy worked that well in humans, it would be a game-changing treatment for diabetes.

Xu and his colleagues tested the efficacy of a combination of experimental drugs, dasatinib and quercetin. Dasatinib and quercetin have already been shown to extend lifespan and good health in aged mice [2]. In this study, researchers found these drugs can kill senescent cells from cultures of human fat tissue. The tissue was donated by individuals with obesity who were known to have metabolic troubles. Without treatment, the human fat tissues induced metabolic problems in immune-deficient mice; however, after treatment with dasatinib and quercetin, the harmful effects of the fat tissue were almost eliminated.

“These drugs can make human fat healthy, and that could be great,” says Xu. “The results were very impressive and cleared the route for potential clinical trials [3].”

Indeed, Xu and his colleagues at UConn and the Mayo Clinic are now pursuing using the dasatinib and quercetin combination in clinical trials to see if the drugs can improve Type 2 diabetes in human patients.

“Although these preclinical results were very promising, large-scale clinical trials are absolutely critical to examine the efficacy and safety of these drugs in humans before clinical use,” emphasised Xu [3].

The research team is also focusing on a previously unexplored senescent cell population. These senescent cells express high levels of p21, a cyclin-dependent kinase inhibitor, and one of the key markers for cellular senescence. By using a newly developed mouse model, Xu’s team demonstrated that clearance of these senescent cells once every month is effective for both slowing down the development of diabetes and alleviating developed diabetic symptoms in obese mice [4]. Xu says previous research has focused on different cell markers, but that the effects of clearing away cells highly expressing p21 was so marked on alleviating diabetes that this marker should get more attention.

[1] https://www.sciencedirect.com/science/article/abs/pii/S1550413121005301
[2] https://www.nature.com/articles/s41591-018-0092-9
[3] https://today.uconn.edu/2021/11/uconn-researchers-deleting-dysfunctional-cells-alleviates-diabetes/
[4] https://www.nature.com/articles/s43587-021-00107-6

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Genflow IPO “starts a new chapter” for longevity biotech

Company floats on London Stock Exchange and becomes Europe’s first publicly traded longevity biotech. Today, Genflow Biosciences became the first longevity biotech IPO of 2022...

Roll up, roll up… it’s the Longevity Biotech Virtual Job Fair!

Amplifying the longevity biotech space with exciting opportunities and brand-new start. The new year brings new opportunities, and the new Longevity Biotech Virtual Job Fair...

    Subscribe to our newsletter